NEA Secondary
Venture capitalTimonium · 7 people tracked
Find your way into NEA Secondary
824 people in our graph share verified history with the NEA Secondary team — schools, employers, funds. One of them is your warm intro.
.jpeg)
Fund manager profile
NEA Secondary is a venture fund manager based in Timonium. SEC filings show 1 venture fund on record, most recently NEA Secondary Opportunity Fund, L.P. ($468.2M offering) filed July 2024.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 7 people
from public directories
What they invest in
from 7 of 8 portfolio companiesBiotech ×6Healthtech ×3Deep Tech ×2Medical Devices ×2AI & Machine Learning ×1
HQs:United States×8
Investments · 8 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 22023 · 22022 · 12021 · 18 dated
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)
BoardDonald Tang(Director)
Board seatEdward Mathers· per SEC Form D · $40M raise · filed Jun 2026
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLux CapitalMenlo VenturesNew Enterprise Associates (NEA)+3 more
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)
Board seatEdward Mathers· per SEC Form D · $45M raise · filed Oct 2025
Co-investorsAtlas VentureEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)+1 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Board seatAli Behbahani· per SEC Form D · $100M raise · filed Feb 2023
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+2 more
BiotechDover, US
Iain Dukes(Executive Officer, Director)Nikolay Savchuk(Executive Officer, Director)
BoardKeno Gutierrez(Director)Michele Cucullu(Director)
Board seatEdward Mathers· per SEC Form D · $65M raise · filed Jul 2024
Co-investorsNew Enterprise Associates (NEA)
HealthtechForest Lake, US
Steve Goedeke(Executive Officer, Director)
BoardKaren Shanahan(Director)William Abraham(Director)Michael DeMane(Director)Jay Graf(Director)
Board seatAli Behbahani· per SEC Form D · $11.5M raise · filed Oct 2021
Co-investorsAscension VenturesNew Enterprise Associates (NEA)
BiotechBurlington, US
Michael Mendelsohn(Executive Officer, Director)
BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Adam Koppel(Director)inNicholas Downing(Director)
Board seatEdward Mathers· per SEC Form D · $260.4M raise · filed Jul 2024
Co-investorsBain Capital Life SciencesBain CapitalBain Capital Tech OpportunitiesPolaris PartnersThird Rock Ventures
Sorriso Pharma is a biopharmaceutical company backed by leading venture capital firms specializing in life sciences and healthcare investments.
BiotechHealthtechMedical DevicesSandy, US
Ciara Kennedy, Ph.D.(Executive Officer, Director)Brian Dorsey(Executive Officer)Michael Grey(Director)Mark Chin(Director)Susan Dube(Executive Officer)
Board seatEdward Mathers· per SEC Form D · $31.4M raise · filed Jan 2022
Co-investorsNew Enterprise Associates (NEA)Pappas Capital
San Francisco, US
Rajaie Batniji(Executive Officer, Director)inSanjay Basu(Executive Officer, Director)in
BoardVineeta Agarwala(Director)in
Board seatMohamad Makhzoumi· per SEC Form D · $22M raise · filed Nov 2023
Co-investorsAndreessen Horowitz
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioSenti BiosciencesNASDAQ: SNTI
Portfolio news
latest coverage across their companies
Arcellx · biobuzz.io · Aug 14, 2026
Senti Biosciences · kalkine.com.au · Jul 31, 2026
Affinia Therapeutics · clinicaltrialsarena.com · Feb 5, 2026
Cardionomic · sciencedirect.com · Oct 8, 2025
Frequently asked questions
- Where is NEA Secondary located?
- NEA Secondary is headquartered in Timonium, US.